Mixing and Matching Vaccines
The CDC might reverse course again, this time on mixing vaccine formularies. We review the science and politics underlying the...
Modern Day Fertility Crisis
A recent report erroneously attributes decreasing fertility rates to personal choice among women, conflating economic trends with personal decisions.
Crafting a Vaccine Marketing Campaign
We see many newly minted vaccine campaigns motivating those eligible to get vaccinated. We analyze why these campaigns will fail.
Healthcare Equity in Medical Education
The AAMC launched an initiative encouraging medical schools to study healthcare equity - a laudable goal, but one that can...
End of Year Healthcare IPO Bubble
Many highly valued healthcare startups are struggling as public companies, leading many to believe a healthcare bubble is on the...
Card Stacking COVID-19 Boosters
The FDA approved a booster dose for COVID-19 vaccines. A sensible decision, but we are concerned at how they derived...
Curious Case of Rising Death Rates
A report by NBER reveals stark disparities in American mortality, which may redefine how we see healthcare.
Art of the Startup
The perceptions of healthcare entrepreneurship differ from its realities. This is why many healthcare startups fail.
America’s Abortion Obsession
The United States has a long history of restricting abortions, using the pretense of medicine to enact laws that moralize...
Why Healthcare Laws are Restrictive
Healthcare laws restrict specific aspects of healthcare behavior. But in restricting, they reduce complex behavior into simplified restrictions.
Israeli Data, American Policy
Israel has become an international leader in COVID-19 research. But we should question whether we can apply Israeli data into...
Afghan Shock on Healthcare
The war on drugs has become an international battle, with foreign policy affecting healthcare domestically. The recent events in Afghanistan...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more